Journal article
Baseline use of aspirin or statins with oral estrogen and progestogens to prevent incident arterial or venous thrombotic events: a secondary analysis of the Women's Health Initiative trial
Menopause (New York, N.Y.), v 33(2), pp 134-144
01 Feb 2026
PMID: 41117635
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Objective:To evaluate whether effects of oral hormone therapy (HT) on risks of venous and arterial vascular events differ by baseline statin or aspirin use.Methods:We performed time-to-event analysis using data from the Women's Health Initiative menopausal HT randomized trials to assess risk of thrombotic events. Women were randomized to oral conjugated equine estrogens (CEEs) alone or placebo among women with prior hysterectomy (n = 10,739), and CEE with medroxyprogesterone acetate (MPA) or placebo among women with an intact uterus (n = 16,608), stratified by baseline personal use of statins and aspirin. We evaluated risk of prespecified, adjudicated thrombotic events, including coronary heart disease, stroke, venous thromboembolism, and/or composite major adverse cardiovascular events, at 2 and 5 years.Results:Baseline statin use (n = 827 in CEE-alone trial; n = 1,115 in CEE+MPA trial) or aspirin use (n = 2,212; n = 3,431) was limited. At 5-year follow-up, coronary heart disease risk for CEE-alone versus placebo was hazard ratio (HR) = 0.81 (95% CI: 0.44-1.49) in statin users, similar to nonusers, HR = 1.07 (95% CI: 0.82-1.40). For CEE+MPA, there was also no difference by statin use, HR = 1.02 (95% CI: 0.55-1.89) and HR = 1.47 (95% CI: 1.13-1.90), respectively. Neither statin nor aspirin exposure significantly modified effects of HT on any arterial or venous thrombotic outcome at 2 or 5 years.Conclusions:In this secondary randomized clinical trial analysis, neither statins nor aspirin significantly modified effects of oral HT on key arterial or venous thrombotic outcomes at 2 or 5 years. Results, however, may be underpowered given low baseline exposure prevalence for both statins and aspirin.
Metrics
1 Record Views
Details
- Title
- Baseline use of aspirin or statins with oral estrogen and progestogens to prevent incident arterial or venous thrombotic events: a secondary analysis of the Women's Health Initiative trial
- Creators
- John W. Davis - Barnes-Jewish HospitalAaron K. Aragaki - Fred Hutch Cancer CenterLaura B. Harrington - Kaiser PermanenteJacques E. Rossouw - National Heart Lung and Blood InstituteGretchen Wells - University of Alabama at BirminghamAladdin Shadyab - University of California San DiegoPeter F. Schnatz - Drexel UniversityChrisandra L. Shufelt - Jacksonville CollegeLisa Warsinger-Martin - Gen Digital Inc. (United States)Robert A. Wild - University of Oklahoma Health Sciences CenterJoann E. Manson - Brigham and Women's Hospital
- Publication Details
- Menopause (New York, N.Y.), v 33(2), pp 134-144
- Publisher
- Lippincott Williams & Wilkins
- Number of pages
- 11
- Grant note
- National Heart, Lung, and Blood Institute; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Obstetrics and Gynecology
- Web of Science ID
- WOS:001673185700010
- Scopus ID
- 2-s2.0-105028871029
- Other Identifier
- 991022196569904721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
Source: SDGs in the Output
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Obstetrics & Gynecology